Aktienanalyse zu Minerva Neurosciences Inc (NERV)NERVMinerva Neurosciences Inc

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Minerva Neurosciences Inc appears to be a good buy right now due to its recent price target from analysts, with Citizens setting a target of $14, which indicates a potential upside of approximately 189% from the current price of $4.84. Additionally, the company has shown a significant 1-year change of +113.69%, reflecting strong growth momentum. However, the main risk is the negative earnings per share reported at -0.46 for the last quarter, indicating ongoing profitability challenges.

3 analysts cover NERV: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 4.50.